Nautilus Biotechnology Files $300M Shelf Registration, Including $125M Nasdaq Common Stock ATM Offering Through TD Cowen
-SEC Filing
Stocks · News reference
Leerink Partners Initiates Coverage On Nautilus Biotechnology with Outperform Rating, Announces Price Target of $4
Leerink Partners analyst Puneet Souda initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Outperform rating and announces Price Target of $4.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Nautilus Biotechnology, Inc. (NAUT)
Filed: 2026-09-11 AccNo: 0001808805-26-000041 Size: 501 KB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Nautilus Biotechnology shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $4 price target.